Genzyme Receives FDA Fast-Track Status for Fabry Disease Drug

U.S. regulators have awarded fast-track designation to Genzyme’s investigational treatment for Fabry disease. Fabry disease is a rare genetic disorder affecting an approximate 10,000 people around the globe. More information on this treatment and the fast-track program available here. (Source: PharmaTimes Digital, 4/28/15)

You might also be interested in:

Guidepaper Looks to Help Health Plans Cut Avoidable Expenses… November 19, 2018
Pressure Mounts for Pharma Over Transparency September 9, 2018
ICER Provides Policy Recommendations for Opioid Use Disorder Therapies December 3, 2018
MAPS Sponsoring PharmaTimes Medical and Scientific Excellence Awards August 31, 2018
ICER Releases Report on Extended-Release Medications for… October 29, 2018
NICE Provides First Advice on Patient Preference Study Design February 15, 2019
FDA OKs Novartis' $2.1 Million SMA Treatment May 28, 2019